You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Colorcon
Medtronic
McKinsey
Harvard Business School

Last Updated: March 30, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Amylamine


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Amylamine?

Amylamine is an investigational drug.

There have been 19 clinical trials for Amylamine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 18th 2019.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Yale University, Targacept Inc., and CoMentis.

There are two US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for Amylamine
TitleSponsorPhase
Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar HyperhidrosisAtacama TherapeuticsPhase 2
Pilot Study of Mecamylamine for Autonomic Dysreflexia ProphylaxisWayne State UniversityPhase 4
Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar HyperhidrosisAtacama TherapeuticsPhase 2

See all Amylamine clinical trials

Clinical Trial Summary for Amylamine

Top disease conditions for Amylamine
Top clinical trial sponsors for Amylamine

See all Amylamine clinical trials

US Patents for Amylamine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Amylamine   Start Trial Process for protecting bearings in steel mills and other metal processing mills Amoco Corporation (Chicago, IL)   Start Trial
Amylamine   Start Trial Preparation of organometallic amide compositions Lithium Corporation of America (Gastonia, NC)   Start Trial
Amylamine   Start Trial Process for obtaining ceric oxide Rhone-Poulenc Chimie (Courbevoie, FR)   Start Trial
Amylamine   Start Trial Catalyst for the amination of alcohols under hydrogenating conditions BASF Aktiengesellschaft (Ludwigshafen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Colorcon
Dow
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.